Brianna R Murphy1,2,3, Margaret P Raber1,3, Karla D Crawford1,3, Leslie Grasse1, Lisa Wartenberg1, Jimin Wu4, Seyedeh S Dibaj4, Joya Chandra1,3. 1. Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Pediatric Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Center for Energy Balance in Cancer Prevention and Survivorship, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
Background: Subtypes of pediatric oncology patients and childhood cancer survivors who are overweight or obese have worse prognosis than their healthy-weighted peers. Several studies have examined weight status in either pediatric patients or survivors with acute leukemia, but few have compared these data across various diagnoses. Objectives: We examined BMI from oncology diagnosis or presentation, through treatment, and into survivorship across the most common cancer types seen in pediatric oncology. Methods: Patients were categorized into three oncologic diagnoses: leukemia and lymphoma (n = 69), neural tumors (n = 80), and non-neural solid tumors (n = 80) at yearly intervals over the course of 11 years. To allow for comparisons across age groups, BMI percentiles were calculated with <5th percentile classified as underweight (n = 11), the 5th-84th percentile classified as a healthy weight (n = 129), and above the 85th percentile classified as overweight and obese (n = 87). Results: At presentation, 45.6% of leukemia and lymphoma patients were overweight or obese, and 44.3% of neural tumor patients were overweight or obese. These high obesity rates persisted into survivorship. Compared to the non-neural tumor group, the leukemia and lymphoma group had a significant increase in BMI percentile over time, while the neural tumor group did not. Conclusions: Pediatric patients with leukemia, lymphoma, and neural tumors and who are overweight or obese at presentation continue this trend into survivorship, indicating a need for management of overweight and obesity through lifestyle interventions concurrent with therapy.
Background: Subtypes of pediatric oncology patients and childhood cancer survivors who are overweight or obese have worse prognosis than their healthy-weighted peers. Several studies have examined weight status in either pediatric patients or survivors with acute leukemia, but few have compared these data across various diagnoses. Objectives: We examined BMI from oncology diagnosis or presentation, through treatment, and into survivorship across the most common cancer types seen in pediatric oncology. Methods:Patients were categorized into three oncologic diagnoses: leukemia and lymphoma (n = 69), neural tumors (n = 80), and non-neural solid tumors (n = 80) at yearly intervals over the course of 11 years. To allow for comparisons across age groups, BMI percentiles were calculated with <5th percentile classified as underweight (n = 11), the 5th-84th percentile classified as a healthy weight (n = 129), and above the 85th percentile classified as overweight and obese (n = 87). Results: At presentation, 45.6% of leukemia and lymphomapatients were overweight or obese, and 44.3% of neural tumorpatients were overweight or obese. These high obesity rates persisted into survivorship. Compared to the non-neural tumor group, the leukemia and lymphoma group had a significant increase in BMI percentile over time, while the neural tumor group did not. Conclusions: Pediatric patients with leukemia, lymphoma, and neural tumors and who are overweight or obese at presentation continue this trend into survivorship, indicating a need for management of overweight and obesity through lifestyle interventions concurrent with therapy.
Authors: Aeltsje Brinksma; Petrie F Roodbol; Esther Sulkers; Willem A Kamps; Eveline S J M de Bont; Annemieke M Boot; Johannes G M Burgerhof; Rienk Y J Tamminga; Wim J E Tissing Journal: Clin Nutr Date: 2014-01-23 Impact factor: 7.324
Authors: Christopher J C Marriott; Lesley F Beaumont; Troy H Farncombe; Amy N Cranston; Uma H Athale; Valerie N Yakemchuk; Colin E Webber; Ronald D Barr Journal: Cancer Date: 2017-12-12 Impact factor: 6.860
Authors: Jennifer Cohen; Claire E Wakefield; Catharine A K Fleming; Rebecca Gawthorne; Linda C Tapsell; Richard J Cohn Journal: Pediatr Blood Cancer Date: 2011-08-17 Impact factor: 3.167
Authors: Beverly J Lange; Robert B Gerbing; James Feusner; Jeffrey Skolnik; Nancy Sacks; Franklin O Smith; Todd A Alonzo Journal: JAMA Date: 2005-01-12 Impact factor: 56.272
Authors: Paul C Rogers; Lillian R Meacham; Kevin C Oeffinger; David W Henry; Beverly J Lange Journal: Pediatr Blood Cancer Date: 2005-12 Impact factor: 3.167
Authors: Hanneke M van Santen; Ronald B Geskus; Steven Raemaekers; A S Paul van Trotsenburg; Thomas Vulsma; Helena J H van der Pal; Hubert N Caron; Leontien C M Kremer Journal: Cancer Date: 2015-08-19 Impact factor: 6.860